Go Pro
→ The REAL Reason Trump is Invading Iran (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$81.07
-0.5%		$79.11
$46.81
▼
$93.42
$15.93B0.962.30 million shs1.11 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$138.89
-4.3%		$70.22
$22.28
▼
$176.66
$57.94B0.9124.03 million shs31.49 million shs
Natera, Inc. stock logo
NTRA
Natera
$327.72
-1.3%		$276.45
$157.43
▼
$333.56
$47.86B1.511.46 million shs1.22 million shs
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
$211.58
+1.0%		$189.02
$35.62
▼
$220.34
$44.89B1.391.70 million shs1.60 million shs
Options Trading Made Easy - Download Now Cover
Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-0.53%+1.48%-3.51%+19.70%+65.18%
Moderna, Inc. stock logo
MRNA
Moderna
-4.26%+115.47%+156.87%+195.32%+412.13%
Natera, Inc. stock logo
NTRA
Natera
-1.30%+4.31%+25.09%+63.12%+97.90%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
+1.01%-0.20%+11.81%+36.60%+471.68%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$81.07
-0.5%		$79.11
$46.81
▼
$93.42
$15.93B0.962.30 million shs1.11 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$138.89
-4.3%		$70.22
$22.28
▼
$176.66
$57.94B0.9124.03 million shs31.49 million shs
Natera, Inc. stock logo
NTRA
Natera
$327.72
-1.3%		$276.45
$157.43
▼
$333.56
$47.86B1.511.46 million shs1.22 million shs
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
$211.58
+1.0%		$189.02
$35.62
▼
$220.34
$44.89B1.391.70 million shs1.60 million shs
Options Trading Made Easy - Download Now Cover
Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-0.53%+1.48%-3.51%+19.70%+65.18%
Moderna, Inc. stock logo
MRNA
Moderna
-4.26%+115.47%+156.87%+195.32%+412.13%
Natera, Inc. stock logo
NTRA
Natera
-1.30%+4.31%+25.09%+63.12%+97.90%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
+1.01%-0.20%+11.81%+36.60%+471.68%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
2.83
Moderate Buy$100.7924.32% Upside
Moderna, Inc. stock logo
MRNA
Moderna
2.00
Hold$74.31-46.50% Downside
Natera, Inc. stock logo
NTRA
Natera
2.82
Moderate Buy$319.38-2.55% Downside
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
2.90
Moderate Buy$167.89-20.65% Downside

Current Analyst Ratings Breakdown

Latest BBIO, MRNA, NTRA, and RVMD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/24/2026
Moderna, Inc. stock logo
MRNA
Moderna
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetEqual Weight$48.00 ➝ $125.00
8/21/2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Sanford C. Bernstein logo
Sanford C. Bernstein
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetMarket Perform$151.00 ➝ $179.00
8/21/2026
Moderna, Inc. stock logo
MRNA
Moderna
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetUnderweight$40.00 ➝ $77.00
8/20/2026
Moderna, Inc. stock logo
MRNA
Moderna
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$50.00 ➝ $150.00
8/20/2026
Moderna, Inc. stock logo
MRNA
Moderna
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetEqual Weight$39.00 ➝ $89.00
8/19/2026
Moderna, Inc. stock logo
MRNA
Moderna
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral
8/19/2026
Moderna, Inc. stock logo
MRNA
Moderna
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$67.00 ➝ $120.00
8/19/2026
Moderna, Inc. stock logo
MRNA
Moderna
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSector Perform$130.00
8/19/2026
Moderna, Inc. stock logo
MRNA
Moderna
Loop Capital logo
Loop Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$135.00
8/19/2026
Moderna, Inc. stock logo
MRNA
Moderna
Brookline Capital Markets logo
Brookline Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/19/2026
Moderna, Inc. stock logo
MRNA
Moderna
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold
(Data available from 8/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$502.08M31.57N/AN/A($10.77) per share-7.53
Moderna, Inc. stock logo
MRNA
Moderna
$1.94B28.52N/AN/A$22.14 per share6.27
Natera, Inc. stock logo
NTRA
Natera
$2.71B17.45N/AN/A$12.38 per share26.47
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
$11.58M3,916.24N/AN/A$8.44 per share25.07
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$724.93M-$3.57N/AN/AN/A-97.03%N/A-61.19%10/28/2026 (Estimated)
Moderna, Inc. stock logo
MRNA
Moderna
-$2.82B-$7.99N/AN/AN/A-141.43%-28.30%-19.39%11/5/2026 (Estimated)
Natera, Inc. stock logo
NTRA
Natera
-$208.16M-$1.36N/A32,772.00N/A-7.11%-11.38%-7.87%11/5/2026 (Estimated)
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-$1.13B-$8.82N/AN/AN/AN/A-88.20%-57.85%11/4/2026 (Estimated)

Latest BBIO, MRNA, NTRA, and RVMD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/10/2026Q2 2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$0.5756-$0.78-$0.2044-$0.78$220.91 million$243.68 million
8/6/2026Q2 2026
Natera, Inc. stock logo
NTRA
Natera
-$0.4939-$0.47+$0.0239-$0.47$661.24 million$752.75 million
8/5/2026Q2 2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-$2.04-$3.06-$1.02-$3.06$1.77 millionN/A
7/31/2026Q2 2026
Moderna, Inc. stock logo
MRNA
Moderna
-$2.03-$1.97+$0.06-$1.97$102.93 million$145.00 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/AN/AN/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
Natera, Inc. stock logo
NTRA
Natera
N/AN/AN/AN/AN/A
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/A
1.23
1.17
Moderna, Inc. stock logo
MRNA
Moderna
0.09
2.29
2.18
Natera, Inc. stock logo
NTRA
Natera
N/A
3.00
2.85
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
0.40
11.38
11.38

Institutional Ownership

CompanyInstitutional Ownership
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
99.85%
Moderna, Inc. stock logo
MRNA
Moderna
75.33%
Natera, Inc. stock logo
NTRA
Natera
99.90%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
94.34%

Insider Ownership

CompanyInsider Ownership
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
14.23%
Moderna, Inc. stock logo
MRNA
Moderna
10.80%
Natera, Inc. stock logo
NTRA
Natera
5.05%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
7.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
400195.49 million167.67 millionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
4,700399.24 million356.12 millionOptionable
Natera, Inc. stock logo
NTRA
Natera
6,140144.14 million136.87 millionOptionable
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
250214.34 million198.05 millionOptionable

Recent News About These Companies

Revolution Medicines (NASDAQ:RVMD) Raised to Strong-Buy at TD Cowen
 |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-revolution-medicines-nasdaq-rvmd-raised-to-strong-buy-at-td-cowen-2026-08-25/
Nan Fung Group Holdings Ltd Takes Position in Revolution Medicines, Inc. $RVMD
 |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-nan-fung-group-holdings-ltd-takes-position-in-revolution-medicines-inc-rvmd-2026-08-25/
Korea Investment CORP Purchases New Stake in Revolution Medicines, Inc. $RVMD
 |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-korea-investment-corp-purchases-new-stake-in-revolution-medicines-inc-rvmd-2026-08-25/
Billionaire Stanley Druckenmiller Continues to Load Up on Revolution Medicines. Does He Know Something Wall Street Doesn't?
 |  fool.comhttps://www.fool.com/investing/2026/08/25/billionaire-stanley-druckenmiller-continues-to-loa/
Daiichi Life Insurance Co. Ltd. Acquires Shares of 5,523 Revolution Medicines, Inc. $RVMD
 |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-daiichi-life-insurance-co-ltd-acquires-shares-of-5523-revolution-medicines-inc-rvmd-2026-08-25/
Bank of Nova Scotia Takes $13.84 Million Position in Revolution Medicines, Inc. $RVMD
 |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-nova-scotia-takes-1384-million-position-in-revolution-medicines-inc-rvmd-2026-08-25/
Bank of New York Mellon Corp Invests $112.57 Million in Revolution Medicines, Inc. $RVMD
 |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-new-york-mellon-corp-invests-11257-million-in-revolution-medicines-inc-rvmd-2026-08-25/
Revolution Medicines, Inc. (NASDAQ:RVMD) Receives Average Rating of "Moderate Buy" from Analysts
August 25 at 2:15 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30981236
Revolution Medicines, Inc. (NASDAQ:RVMD) Given Average Recommendation of "Moderate Buy" by Brokerages
August 25 at 2:13 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-revolution-medicines-inc-nasdaq-rvmd-given-average-recommendation-of-moderate-buy-by-brokerages-2026-08-25/
58,834 Shares in Revolution Medicines, Inc. $RVMD Bought by Ieq Capital LLC
August 23 at 5:36 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-58834-shares-in-revolution-medicines-inc-rvmd-bought-by-ieq-capital-llc-2026-08-23/
B. Metzler seel. Sohn & Co. AG Makes New $2.55 Million Investment in Revolution Medicines, Inc. $RVMD
August 23 at 3:11 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-b-metzler-seel-sohn-co-ag-makes-new-255-million-investment-in-revolution-medicines-inc-rvmd-2026-08-23/
Danske Bank A S Makes New $14.83 Million Investment in Revolution Medicines, Inc. $RVMD
August 21, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-danske-bank-a-s-makes-new-1483-million-investment-in-revolution-medicines-inc-rvmd-2026-08-21/
Revolution Medicines Advances RASolve 308 Lung Cancer Trial, Raising Long-Term Upside Potential for RVMD
August 20, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/revolution-medicines-advances-rasolve-308-lung-cancer-trial-raising-long-term-upside-potential-for-rvmd?utm_source=marketbeat.com&utm_medium=referral
Mitsubishi UFJ Asset Management Co. Ltd. Takes Position in Revolution Medicines, Inc. $RVMD
August 20, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-mitsubishi-ufj-asset-management-co-ltd-takes-position-in-revolution-medicines-inc-rvmd-2026-08-20/
Eagle Health Investments LP Buys New Position in Revolution Medicines, Inc. $RVMD
August 20, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-eagle-health-investments-lp-buys-new-position-in-revolution-medicines-inc-rvmd-2026-08-20/
Deutsche Bank AG Makes New Investment in Revolution Medicines, Inc. $RVMD
August 20, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-deutsche-bank-ag-makes-new-investment-in-revolution-medicines-inc-rvmd-2026-08-20/
Citizens Financial Group Inc. RI Buys New Position in Revolution Medicines, Inc. $RVMD
August 18, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-citizens-financial-group-inc-ri-buys-new-position-in-revolution-medicines-inc-rvmd-2026-08-18/
Alphabet Inc. Makes New Investment in Revolution Medicines, Inc. $RVMD
August 18, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-alphabet-inc-makes-new-investment-in-revolution-medicines-inc-rvmd-2026-08-18/
Revolution Medicines (NASDAQ:RVMD) Sets New 52-Week High - Here's Why
August 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/revolution-medicines-nasdaqrvmd-sets-new-52-week-high-heres-why-2026-08-17/
Persistent Asset Partners Ltd Makes New $7.25 Million Investment in Revolution Medicines, Inc. $RVMD
August 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-persistent-asset-partners-ltd-makes-new-725-million-investment-in-revolution-medicines-inc-rvmd-2026-08-17/
Renaissance Technologies LLC Takes $603,000 Position in Revolution Medicines, Inc. $RVMD
August 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-renaissance-technologies-llc-takes-603000-position-in-revolution-medicines-inc-rvmd-2026-08-17/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
A Patriot missile launcher and soldier on an airbase tarmac as an F-35 fighter jet flies overhead at sunset.
RTX and Lockheed Earnings: Can Strong Guidance Reset the Defense Trade?
By Dan Schmidt | July 26, 2026
Atlassian logo displayed on an illuminated glass panel in a blue-lit setting with a cloud icon in the background.
Atlassian Just Pulled Off the Software Comeback Wall Street Wanted
By Dan Schmidt | August 11, 2026
Illustration showing Hims & Hers logo and app connected through a security checkpoint icon to the Visa logo and card.
Visa Just Put Hims & Hers in the Penalty Box—Here’s Why It Matters
By Jeffrey Neal Johnson | August 24, 2026
Rocket Lab logo displayed on a sign with a rocket on a launch pad at sunset in the background.
Rocket Lab’s Record Quarter Still Left Investors Waiting on Neutron
By Ryan Hasson | August 11, 2026
SpaceX logo above a rocket on a launch pad at twilight, with a water tower in the background.
Lost in Space: Why Aerospace Valuations Are Plummeting Right Now
By Jeffrey Neal Johnson | August 1, 2026
BridgeBio Pharma stock logo

BridgeBio Pharma NASDAQ:BBIO

$81.07 -0.43 (-0.53%)
Closing price 08/24/2026 04:00 PM Eastern
Extended Trading
$81.06 -0.01 (-0.02%)
As of 04:29 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Moderna stock logo

Moderna NASDAQ:MRNA

$138.89 -6.24 (-4.30%)
Closing price 08/24/2026 04:00 PM Eastern
Extended Trading
$141.10 +2.21 (+1.59%)
As of 07:30 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Natera stock logo

Natera NASDAQ:NTRA

$327.72 -4.31 (-1.30%)
Closing price 08/24/2026 04:00 PM Eastern
Extended Trading
$328.97 +1.25 (+0.38%)
As of 07:23 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.

Revolution Medicines stock logo

Revolution Medicines NASDAQ:RVMD

$211.58 +2.12 (+1.01%)
Closing price 08/24/2026 04:00 PM Eastern
Extended Trading
$212.50 +0.92 (+0.43%)
As of 07:26 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas